PerpEquities

SELLAS Life Sciences Group, Inc. (SLS)财务

NASDAQ · Healthcare · Biotechnology · 员工13人 · CEO Angelos Stergiou

股价
$14.69 +2.0%
市值
$27.8亿
企业价值
$26.5亿 数据截至 2026-11-21
最近财报
Q3 '26 2026-11-12提交
下次财报
2027-03-25 EPS预期 -$0.05
营收(TTM)$0– 对比去年同期最近4个季度;柱状图=各季度
营业利润率(TTM)–– 对比去年同期营业利润 -$3940万
净利润(TTM)-$3580万-37.8% 对比去年同期税后,含营业外收益
自由现金流(TTM)-$2730万+10.9% 对比去年同期资本支出 $0
稀释EPS(TTM)-$0.20+31.5% 对比去年同期最近4个季度之和
净现金$1.34亿+206.0% 对比去年同期现金 + 短期投资 - 债务

估值与关键数据

市值
$27.8亿
3h 前更新
营收
$0
过去12个月
营收增速
–
FY2026年一致预期
净利润率
–
净利润 / 营收,TTM
P/E
无市盈率
过去十二个月亏损
P/S
–
股价 / 营收,TTM
EV / EBITDA
-74.1×
TTM
自由现金流
-$2730万
过去12个月
净利润
-$3580万
过去12个月
营收预期
$3610万
FY2026年一致预期
盈利
2027-03-25
营收预估 $3610万 · 3h 前更新
股息
–
无股息

核心要点

根据披露数据计算,每条结论都附有其依据的数字。

  • 最近财报(2026-11-12):营收无,EPS 符合预期营收–,预期–(–);EPS -$0.05,预期-$0.05(0.0%)。
  • 稀释股数一年内增加86.8%Q3 '26稀释股数2.02亿,一年前为1.08亿。
  • 净现金 $1.34亿现金 + 短期投资 $1.35亿,含租赁债务 $59.9万;一年前净现金 $4380万。

上一季度:Q3 '26

截至2026-09-30的季度。与去年同期及财报发布前的分析师一致预期对比。

本季度与去年同期

Q3 '26去年同期变化
营收$0$0–
营业利润-$1130万-$708万-59.7%
净利润-$1010万-$679万-48.6%
稀释EPS-$0.05-$0.06+20.1%
经营现金流-$594万-$707万+16.0%
资本支出$0$0–
自由现金流-$594万-$707万+16.0%
R&D$703万$422万+66.7%
股权激励费用$193万$50.3万+284.1%

实际 vs 一致预期

2026-11-12
实际一致预期对比预期
EPS(一致预期口径)-$0.05-$0.050.0%

来自2026-11-12发布的Q3 '26财报:营收及分析师预期口径的EPS(通常为调整后),可能与上方报表中的EPS不同。

EPS与一致预期

最近8次财报

营收

收入从何而来,按业务线和地区逐季展示。

营收、营业利润与增速

季度

利润率与成本结构

每一单位营收在各层级还剩多少,成本又花在哪里。

利润率

季度

成本占营收比例

季度

现金流与资本配置

创造了多少现金,用在何处,又有多少回到股东手中。

经营现金流、资本支出、自由现金流

季度

现金用途与经营现金流

财年

最近4个季度

现金流量表
经营现金流
-$2730万
资本支出
$0
股票回购
$0
股息
$0
收购
$0
债务净发行
$0
股权激励费用
$419万
自由现金流
-$2730万
股东回报 / FCF
0.0%

股数与EPS

季度,稀释

资产负债表

各季度末的流动性、投资和债务。

现金、投资与债务

季度末

估值与回报

当前估值倍数与公司自身过去五个财年对比;分析师目标价与评级。

估值倍数与回报

TTM与过去5个财年
当前5年均值当前处于5年区间的位置
P/E(TTM)–––
EV / EBITDA-74.1×66.5× 5年中的2年52.6× – 80.3×
EV / 营收0.0×19.1× 5年中的2年8.5× – 29.6×
股价 / FCF-102.0×––
股价 / 净资产21.0×6.5× 5年中的4年4.2× – 9.4×
FCF收益率-1.0%-56.0%-125.4% – -6.9%
投入资本回报率-29.8%-127.6%-723.3% – 535.6%
净资产收益率-31.9%-169.8%-851.4% – 468.2%

分析师

一致目标价 $35.00 (+156.2%)
区间 $35.00 – $35.00 · 评级 Buy

强烈买入0
买入5
持有0
卖出0
强烈卖出0

展望

分析师对未来财年的一致预期,以及按当前股价意味着什么。

一致预期

财年营收增速EPS增速按当前股价的P/E分析师(EPS)
FY2026$3610万–-$0.20+20.0%–1
FY2027$5470万+51.3%-$0.25-22.5%–2
FY2028$7890万+44.3%-$0.02+91.8%–2
FY2029$1.86亿+135.5%$0.36+1,900.0%40.8×1
FY2030$7.89亿+324.6%$2.68+644.4%5.5×1

财务报表

利润表、资产负债表和现金流量表的每一项,含12个季度和10个财年,以金额、占营收比例或增速展示。

全部披露项目

SELLAS Life Sciences Group, Inc.在近期10-Q / 10-K文件中标记的全部135项数据,附SEC官方标签和定义,包括附注(租赁、税务、回购、员工等)。

项目(SEC标签)最近季度去年同期同比最近财年上一财年同比
应付账款$209万$231万-9.4%$295万$350万-15.8%
应计负债(流动)$660万$302万+118.4%$353万$547万-35.5%
Accrued Professional Fees, Current$128万$22.4万+471.0%$19万$30.8万-38.3%
资本公积$4.35亿$3.13亿+39.0%$3.46亿$2.58亿+34.3%
Administrative Fees Expense$30万2026-07-24–––––
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount-161万-530万+69.7%6200万5830万+6.5%
APIC, Share-based Payment Arrangement, Increase for Cost Recognition$193万$50.3万+284.1%$196万$156万+25.1%
总资产$1.41亿$5160万+173.7%$7830万$1940万+303.2%
流动资产$1.39亿$4910万+182.5%$7520万$1630万+360.7%
现金及现金等价物$1.35亿$4430万+204.0%$7180万$1390万+417.0%
现金、现金等价物及受限现金$1.35亿$4440万+203.5%$7190万$1400万+414.0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect-$363万$1900万-119.1%$5790万$1140万+409.9%
Class of Warrant or Right, Exercise Price of Warrants or Rights$1.69––$0.75––
Class of Warrant or Right, Outstanding812万6370万-87.2%5850万5600万+4.5%
Common Stock, Capital Shares Reserved for Future Issuance3370万7020万-51.9%6420万6180万+3.9%
Common Stock, Par or Stated Value Per Share$0.00$0.000.0%$0.00$0.000.0%
法定普通股3.5亿3.5亿0.0%3.5亿3.5亿0.0%
已发行普通股2.04亿1.25亿+62.7%1.53亿7400万+107.0%
流通在外普通股2.04亿1.25亿+62.7%1.53亿7400万+107.0%
普通股面值$2万$1.2万+66.7%$1.5万$7000+114.3%
销售成本$0$0–$0$0–
Costs and Expenses$1130万$708万+59.7%$2830万$3150万-10.3%
Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction$02026-03-31$2.1万-100.0%$1.7万$0–
Decrease in Unrecognized Tax Benefits is Reasonably Possible$02025-12-31––$0––
Deferred Tax Assets, Gross$2300万2025-12-31$2110万+9.4%$2300万$2110万+9.4%
Deferred Tax Assets, in Process Research and Development$219万2025-12-31$250万-12.7%$219万$250万-12.7%
Deferred Tax Assets, Net of Valuation Allowance$20.8万2025-12-31$20万+4.0%$20.8万$20万+4.0%
Deferred Tax Assets, Operating Loss Carryforwards$1670万2025-12-31$1410万+18.5%$1670万$1410万+18.5%
Deferred Tax Assets, Other$35.5万2025-12-31$32.4万+9.6%$35.5万$32.4万+9.6%
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost$79.7万2025-12-31$62.2万+28.1%$79.7万$62.2万+28.1%
Deferred Tax Assets, Valuation Allowance$2280万2025-12-31$2090万+9.5%$2280万$2090万+9.5%
Deferred Tax Liabilities, Gross$20.8万2025-12-31$20万+4.0%$20.8万$20万+4.0%
Deferred Tax Liabilities, Net$02025-12-31$0–$0$0–
Defined Benefit Plan, Plan Assets, Contributions by Employer–––$11.7万$12.4万-5.6%
Deposits Assets, Noncurrent$2.5万$3.4万-26.5%$25.7万$26.6万-3.4%
基本每股收益-$0.05-$0.06+16.7%-$0.25-$0.50+50.0%
稀释每股收益-$0.05-$0.06+16.7%-$0.25-$0.50+50.0%
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount–––-$564万––
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent–––21.0%21.0%0.0%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount–––$192万––
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent–––-7.1%-6.6%-7.6%
Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent–––-14.5%2024-12-31-15.3%+5.2%
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount–––$14万––
Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent–––-0.5%––
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount–––-$4.7万––
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent–––0.2%0.2%0.0%
实际所得税率–––0.0%0.0%–
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent–––0.4%2024-12-310.4%0.0%
应付职工薪酬(流动)$157万$142万+10.3%$175万$178万-1.4%
Estimated Litigation Liability, Current$102万2026-06-30––$02018-12-31$130万-100.0%
Gain (Loss) Related to Litigation Settlement-$100万2026-06-30––-$275万2016-12-31-$528万+47.9%
一般及行政费用$428万$287万+49.3%$659万2012-12-31$864万-23.7%
商誉$191万$191万0.0%$191万$191万0.0%
Goodwill, Impaired, Accumulated Impairment Loss$02025-12-31$0–$0$0–
Goodwill, Impairment Loss–––$0$0–
Income (Loss) from Continuing Operations before Income Taxes, Domestic–––-$957万-$954万-0.4%
Income (Loss) from Continuing Operations before Income Taxes, Foreign–––-$1730万-$2130万+19.0%
税前利润–––-$2690万-$3090万+13.0%
所得税费用(收益)–––$0$0–
支付的所得税净额–––$0$0–

来源:SEC companyfacts(每份10-Q / 10-K的XBRL)。现金流量表的季度数据由10-Q标记的年初至今累计数推算。分部拆分带有维度标记,在分部章节中单独展示。

数据来源

报表、分部营收、指标和预期均根据公司文件标准化。分部利润及全部披露项目:SEC EDGAR(XBRL)。 已读取的文件: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30

数据截至 2026-11-21